Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01426269 · ClinicalTrials.gov registry record · Phase 4
Evaluation of Relapse, Efficacy and Safety of Long-term Treatment With Oracea® vs Placebo
A Phase 4 study, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 4
- Development phase
- 235
- Enrollment target
NCT01426269 is a Phase 4 study that has completed, run by Galderma R&D. The registered enrollment target is 235 participants.
The verdict
NCT01426269, a Phase 4 study, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 235 participants
- Enrollment target
Study Summary
The purpose of this study is to assess relapse, efficacy and safety in subjects with rosacea during long-term treatment with either Oracea® or placebo, after an initial 12-week regimen of Oracea® and MetroGel® 1%.
Interventions
- DRUG Placebo
- DRUG Metronidazole
- DRUG Doxycycline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 235 participants |
| Start Date | 2011-09 |
| Est. Completion | 2013-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01426269
The ClinicalTrials.gov registry entry for NCT01426269 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 235 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01426269 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01426269 about?
NCT01426269 is a clinical study titled "Evaluation of Relapse, Efficacy and Safety of Long-term Treatment With Oracea® vs Placebo". The purpose of this study is to assess relapse, efficacy and safety in subjects with rosacea during long-term treatment with either Oracea® or placebo, after an initial 12-week regimen of Oracea® and MetroGel® 1%.
What is the current status of trial NCT01426269?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 235 participants. The study started on 2011-09. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01426269?
The interventions under investigation include: Placebo (DRUG), Metronidazole (DRUG), Doxycycline (DRUG).
Who is sponsoring clinical trial NCT01426269?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.